Clinical Trial Update: Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating the use of epigallocatechin-3-gallate (EGCG) to protect the esophagus in lung cancer patients receiving radiotherapy; current st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagitis
• Lung Cancer

Drugs mentioned

• Epigallocatechin-3-Gallate (epigallocatechin-3-gallate)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Lung Neoplasms, Esophagitis | Phase 2 | Status: UNKNOWN